Children's National Medical Center

Julia C Finkel

Zenaide M N Quezado

The present disclosure is related to a method and apparatus for determining THC usage of a person. The present disclosure describes acquiring a video sequence, of an eye of a patient, the video sequence being a plurality of video frames, determining a frequency spectrum from a pupillary data of the video sequence, and determining, based on the frequency spectrum, the physiological characteristic or drug of use of the patient. In an embodiment, at least one frequency can be probed based on which physiological characteristic is being explored. For example, the physiological characteristic can be Δ#-tetrahydrocannabinol, and the at least one frequency probed can be selected to be specific to Δ#-tetrahydrocannabinol.

Apparatus and method for the non-invasive detection of tetrahydrocannabinol use and impairment

The present disclosure is related to a method and apparatus for determining drug usage or a physiological characteristic of a patient. The present disclosure describes acquiring a video sequence, of an eye of a patient, the video sequence being a plurality of video frames, determining a frequency spectrum from a pupillary data of the video sequence, and determining, based on the frequency spectrum, the physiological characteristic or drug of use of the patient. In an embodiment, at least one frequency can be probed based on which physiological characteristic is being explored.

Bioassay for the non-invasive detection of drug use and physiologic conditions

Described herein is an apparatus and method for generating a pain score for a patient. The method includes the steps of generating a PLR response signature for each drug of a plurality of drugs and further initiating a light stimulus to the patient, and measuring a corresponding PLR response. The method includes initiating a neuro-stimulus to the patient, the neuro-stimulus being initiated over a set of frequencies, each frequency being associated with a unique intensity, and stimulating a unique nerve fiber type of the patient, and measuring a PRD response of the patient for the initiated neuro-stimulus. Further, the method includes determining, for each nerve fiber type, a threshold response based on the measured PRD, determining a weight for each threshold response based on the PLR response, and combining the determined weight for each threshold response to obtain a pain score for the patient.

Apparatus and method for physiologic and pharmacodynamic assessment and monitoring

The present disclosure is related to a method and apparatus for determining a physiologic perturbation of a patient including acquiring a video sequence, including a plurality of video frames, of an eye of a patient, selecting at least one parameter of a plurality of parameters including a baseline pupil size, a maximum change in size of a pupil, an average velocity of constriction of the pupil, a maximum velocity of constriction of the pupil, latency of constriction of the pupil, and a velocity of re-dilation of the pupil, determining, using processing circuitry and based on the plurality of video frames, the selected at least one parameter of the plurality of parameters, and determining the physiologic perturbation of the patient based on the determined at least one parameter, where the least one parameter of the plurality of parameters is selected based on which physiologic perturbation of the patient is to be determined.

Apparatus and method for determining physiologic perturbations of a patient

An apparatus and method for performing human algometry are disclosed. They include a stimulator configured to apply electrical stimulation of variable intensity to an area of a patient's body, a monitoring device configured to measure a level of cortical activity in one or more regions of the patient's brain, and a microprocessor connected to the stimulator and the monitoring device that is configured to correlate the intensity of the electrical stimulation with the level of activity in the one or more regions of the patient's brain and to determine at least one of a measurement of pain intensity, a measurement of a sensory detection threshold (SDT), a measurement of a drug's analgesic impact, an indication of an onset of tolerance to a drug, an indication of an onset of analgesic-induced hyperalgesia, an indication of conditions of allodynia, a measurement of dose-response characteristics of pain management drugs, and a characterization of a pain condition.

Growing community of inventors

Washington, DC, United States of America

Julia C Finkel